Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

/PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics...

Related Keywords

,Daniel Alkon ,Robert Weinstein ,Alan Tuchman ,Exchange Commission ,National Institutes Of Health ,Drug Administration ,Prnewswire Synaptogenix Inc ,Nasdaq ,Synaptogenix Inc ,National Institutes ,Chief Scientific ,Chief Executive Officer ,Orphan Drug Designation ,